Under construction – not a live service
Sign in
Taking people in MoldovaNo phase

Finding Which People With Coronary Artery Disease Face Sudden Cardiac Arrest

Follows adults with coronary artery disease to see who may suffer sudden cardiac arrest.

Key facts

Who runs it
Tampere Heart Hospital
Where
Chisinau, MoldovaSee the siteAlso in 2 other countries, 2 sites
Trial code
Registry title
Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD
Status
Recruiting
People taking part
1,500 people, planned
Started
5 Jan 2025
Expected to end
31 Dec 2027
Type of study
Observational
Record updated
25 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 with coronary artery disease confirmed by imaging in the past 12 months. It studies who is at risk of sudden cardiac arrest.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Coronary artery disease confirmed by coronary angiography or contrast CT within the past 12 months: more than 50% narrowing and/or fractional flow reserve below 0.8, or a type I heart attack from atherosclerosis.

Main reasons for not taking part

  • Cannot give written informed consent, or has a developmental disability or known impaired thinking (MMSE below 23)
  • Serious valve heart disease, or valve treatment needed in the next three months
  • Other heart conditions with a high risk of deadly rhythm problems (for example ARVCD, non-ischemic DCM, HCM, long or short QT syndrome)
  • Serious cancer or other heart disease with life expectancy under 1 year
  • Do-Not-Resuscitate order, or a past or planned heart, kidney or liver transplant

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age ≥ 18 years old
  • Ability to give informed consent
  • Imaging confirmed diagnosis within the past 12 months (coronary artery angiography or contrast enhanced coronary computed tomography); •>50% of stenosis and/or fractional flow-reserve <0.8 verified by selective coronary angiography or by contrast enhanced coronary computed tomography (CT) or type I MI with atherosclerotic origin (despite stenosis percentage)
  • Patients may be recruited during index event visit (out-patient clinic visit, invasive procedure, hospitalization) (or if logistically possible recall patients previously diagnosed within 12 months)

Who cannot take part

  • Clinically significant previously treated valvular heart disease or requiring operative (surgical or endovascular) treatment within following three months
  • Previously done or planned cardiac, renal, or liver transplant
  • Diagnosed severe neurodegenerative disease (ALS, myositis, multiple sclerosis, or Parkinson's disease) or known impaired cognitive function (MMSE <23)
  • Serious/active malignancy with possibly reduced life expectancy of <1 year (estimated by a physician)
  • Other significant cardiac condition severely linked to the risk of fatal ventricular arrhythmia (for example ARVCD, non-ischemic DCM, HCM or genetic long or short QT syndrome)
  • Age > 75 years of age
  • Other cardiac disease with <1 years of life expectancy
  • Known developmental disability impairing legal ability to give written consent
  • Inability to give written consent for some other reason
  • Do-Not-Resuscitate (DNR) order made due to any reason
  • Participation in another clinical trial where the active treatment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in Moldova

Also in 2 other countries, 2 sites

  • Instituția Medico-Sanitară Publică "Institutul de Cardiologie"Chisinau, MoldovaContact: Marcel Abras, MDTaking people

About the trial

What the trial wants to find out

Long-term sudden cardiac death (abbreviation: SCAR) focuses on improving the predictability of sudden cardiac death (SCD) in patients diagnosed with coronary artery disease. The aim of the study is to determine the predictive value of measurable biological variables (including genetic factors, cardiac electrical activity, biological markers measured from circulation, and coronary artery anatomy) as well as the patients' psychosocial factors in predicting SCDs.

Read full original descriptionShow less

The purpose of this study is the identification of a subgroup of coronary artery disease patients at sufficiently high risk in whom it may be possible to prevent sudden cardiac arrests and subsequent deaths using implantable cardioverter-defibrillators. The study is intended to establish a clear foundation for future interventional studies targeting high-risk coronary artery disease patients.

The primary endpoint of the study is SCD/sudden cardiac arrest (SCA) or a comparable malignant arrhythmic event (i.e., resuscitation). Secondary endpoints include other major cardiovascular events occurring during the follow-up period (such as cerebrovascular events, myocardial infarctions, revascularizations, and new arrhythmias like atrial fibrillation following procedures or after the patient has been discharged following recruitment) or the occurrence and mortality of other significant life-threatening diseases (such as cancer). Secondary endpoints also include poor success in secondary prevention, which can be assessed through completed medication purchases and the achievement of secondary prevention goals.

This observational, prospective study includes collecting multimodal data from hospitals in Finland (TAUH), Israel (HYMC), Moldova (IMSP) and Romania (UMFCD). Each participating institution has followed a process structured by Tampere Heart Hospital (TAUH) for securing permissions in line with EU and national regulations.

The group in the trial

  • Patients with coronary artery disease

    Patients with imaging verified coronary artery disease

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD - CVDLINK Clinical Validation Study.
Plain-language title
Finding Which People With Coronary Artery Disease Face Sudden Cardiac ArrestGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07444931, who can take part
Record updated
25 August 2026